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Abstract 
Background: Ischemic strokes, intracranial hemorrhages (ICH) and deep venous thromboembolism 
(DVT) are clinically important events in patients with gliomas.  
Methods: In this multicentre non-interventional observational study current data about frequency, 
contributing factors and outcomes of vascular events in times of anti-angiogenic therapy with the 
antibody against vascular endothelial growth factor, bevacizumab (BEV) was collected in the 
German Glioma Network (GGN).  
Results: Among 3889 glioma patients 70 ischemic strokes (1.8%) and 123 ICH (3.2%) were 
recorded. 143 DVT (5.0%) were recorded in 2855 patients. Rates of DVT and ICH but not of 
ischemic strokes increased with the WHO grade of glioma. 
In 81 BEV-treated patients 5 ischemic strokes (6.2%), 1 ICH (1.2%) and 6 DVT (7.4%) were 
documented. Compared to patients that were not treated with BEV, ischemic stroke rate was 
significantly higher during treatment with BEV (p<0.001). The rates of DVT (p=0.123) or ICH 
(p=0.571) in BEV-treated patients did not differ. On cerebral MRI BEV-related ischemic strokes 
appeared as diffusion-restricted sites next to contrast-enhancing tumor.  
67% of ICH, 61% of ischemic strokes and 18% of DVT occurred postoperatively (within 30 days 
after tumor resection). Outcome after postoperative ICH was significantly worse than that after 
spontaneous ICH (p=0.008). Ischemic stroke outcomes did not differ between post-operative and 
spontaneous occurrence  (p=0.401). Rate of pulmonary embolism did not significantly differ 
between post-operative and spontaneous DVT (p=0.133). 
Discussion: Relatively low rates of ICH and DVT might be partially due to a high proportion of 
low-grade gliomas in this patient cohort. The finding of a relevant number of symptomatic, therapy 
associated intracerebral diffusion restrictions should be controlled in ongoing phase III studies. 
 
Introduction 
Ischemic strokes, intracranial hemorrhages (ICH) and deep venous thromboembolism (DVT) are 
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frequent in patients with glioma [13], [22-24]. 
Consequences may be severe and result in deteriorating quality of life and increasing disability. It is 
assumed that ICH and ischemic strokes [13] are particularly associated with a dismal prognosis. 
Current data about frequency, causes and outcomes of vascular events appear crucial for treating 
physicians, particularly in times of anti-angiogenic therapies and their possible side effects.  
Primary objective of this multicentre non-interventional observational study was a comprehensive 
analysis of spontaneous and postsurgical vascular complications in glioma patients with a special 
focus on the effect of anti-angiogenic therapy with the antibody against vascular endothelial growth 
factor (VEGF), bevacizumab (BEV).  
 
Methods 
Data collection 
Clinical data about ischemic strokes, ICH and DVT in glioma patients (n=3889) have been 
collected in the German Glioma Network (GGN). The GGN is a multicentric (Bochum, Bonn, 
Düsseldorf, Dresden, Freiburg, Hamburg, Heidelberg, München, Tübingen) prospective cohort 
study that enrolled newly diagnosed patients with various types of glioma and frozen tissue 
asservation from October 2004 to October 2010. In addition to the clinical centres there are several 
reference centres for collection and analysis of clinical, pathological and molecular parameters of 
glioma. The patients were not commonly enrolled into clinical trials, and treatment decisions were 
made by the treating physicians, patients and their families, without awareness of results of 
molecular parameters. Progression was defined locally according to Macdonald criteria and not 
centrally reviewed. All patients gave written informed consent. All activities of the GGN have been 
approved by the review boards of the participating institutions. Within the GGN, patients are 
prospectively followed by standardized clinical and MRI examinations. Data are documented on 
CRF and centrally stored and monitored as outlined before (http://www.gliomnetzwerk.de) [28]. 
The GGN did not intend interventions. The GGN established an observational cohort with standard 
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operating procedures for follow up and data acquisition at all levels. 
Between October 2004 and January 2010 data about 3889 patients have been recorded in a central 
database. The clinical centres have centrally recorded vascular complications. The individual 
centers redorded numerous other patient data (age, glioma type, date of resection, adjuvant 
therapies, event related death) on dedicated case record forms for central data storage in addition to 
the basic event data (type and date of event). For completion and amendment of centrally 
documented data additional chart information (clinical outcome, concomitant medication, vascular 
risk factors) have been collected from the centres in 2010 by C.S..  
 
Determination of event rate 
From 3889 patients included between 2004 and 2010 in the GGN rates of ischemic strokes and ICH 
were determined. The DVT rate was calculated from 2855 patients since two clinical centres did not 
document DVT. Occurrence within thirty days after surgery was classified as postoperative.  
Additionally, event rates were calculated for the most frequent glioma types.  
 
Determination of event rate under BEV-treatment and characterisation of events  
Within the GGN patient population 81 patients were treated with BEV. Events were regarded as 
BEV-related when they happened during or max. 4 weeks after BEV-therapy. 
The number of events within 81 patients that were treated with BEV was compared with the number 
of not postoperative events among 3808 patients that were never been treated with BEV.  Detailed 
clinical information and MRI images from BEV-related ischemic strokes were collected from the 
clinical centres. 
 
Comparison of postoperative and non-postoperative events 
All vascular complications were analysed separately according to postoperative or non-
postoperative occurrence.  
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For ischemic strokes the following characteristics were looked at and compared between the two 
groups: patient age, tumor histology, clinical outcome, cerebrovascular risk factors (arterial 
hypertension, diabetes mellitus, atrial fibrillation, persisting foramen ovale) and associated therapy. 
Clinical outcome was determined from clinical data by retrospective estimation of modified rankin 
score (MRS) after the event. This approach has been used before [13] and gives an approximation 
of severity of stroke. It does not take into account the MRS before stroke.   
For ICH patient age, tumor histology, hemorrhage type (intracerebral, subdural, epidural, 
subarachnoidal), clinical outcome (with retrospective modified rankin score) and bleeding risk 
factors (arterial hypertension, thrombocytopenia, use of anticoagulants or aspirine) were determined 
and compared.  
Accordingly, for DVT patient age, tumor histology, clinical outcome (pulmonary embolism, event 
related death), concomitant therapies and use of steroids were looked at.  
 
Statistics 
Categorical data were compared using Fisher's exact or chi-square test. Mann-Whitney-U-test was 
used to analyze age and steroid dose. P-values <0.05 were considered as statistically significant. To 
control the familywise error rate the Holm-Bonferroni Method was applied. Statistical analysis were 
performed using IBM SPPSS V.20 . 
 
Results 
Event rate in the GGN patient population and relation to tumor histologies 
Among 3889 patients 70 ischemic strokes (1.8%) determined clinically and radiographically and 
123 ICH (3.2%) as single events in individual patients, except for one patient with two ischemic 
events, were documented. In addition, 143 DVT (5.0%) were recorded in 2855 patients.  
Distribution of the most frequent gliomas is shown in Table 1. Event rates related to the glioma type 
and WHO grade, namely WHO grade I: pilocytic astrocytoma (PA), WHO grade II: diffuse 
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astrocytoma (AII), oligoastrocytoma (OAII) oligodendroglioma (ODII), WHO grade III: 
(anaplastic) astrocytoma (AA), oligoastrocytoma (AOA), anaplastic oligodendroglioma (AO) and 
glioblastoma (GB) of WHO grade IV are depicted in Table 2.  
The ischemic stroke rate did not differ between tumor entities (p=0.383), whereas ICH rates 
increased significantly with degree of malignancy (p<0.001). Similarly, there was a significant 
correlation between WHO grade and the frequency of DVT (Table 2, p<0.001). Interestingly, in 
case of non-postoperative events this correlation between the WHO grade and frequency of vascular 
events was only seen for DVT  (p<0.001, data not shown). 
 
Rate and characterization of BEV-associated vascular events  
During or maximal four weeks after BEV therapy 6 DVT (7.4%), 1 ICH (1.2%) and 5 ischemic 
strokes (6.2%) in the group of BEV-treated patients (n=81) were documented (Table 3). One patient 
suffered from two ischemic events within eight weeks.  
Among the patients that were never treated with BEV (n=3801) 100 DVT (3.6%), 39 ICH (1.0%) 
and 22 ischemic strokes (0.6%) were registered as non-postoperative events. 
In comparison, ICH rates were similar (1.2% vs. 1.0%, p=0.571). The rate of DVT showed a trend 
for higher frequency under BEV (7.2% vs. 3.6%, p=0.123). Ischemic strokes were more frequent 
during treatment with BEV (6.2% vs. 0.6%, p<0.001).   
As these data indicate a higher frequency of ischemic strokes in patients treated with BEV 
compared with patients never treated with this drug, more detailed clinical data and MRI images 
were analyzed from the 4 affected patients.  
 
All ischemic strokes were situated on the side of the tumor, either in deep white matter, basal 
ganglia or thalamus, all patients had been treated with radiotherapy during the course of disease. 
Median patient age was 63 (59-69), median MRS after the event was 3 (3-6). One patient died 
shortly after the event. Two of four patients showed vascular risk factors. In all patients partial 
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response to BEV was diagnosed. 
In the analysis of the 3/5 available MRI scans lacunary rather than territory diffusion-restricted 
areas in proximity to residual contrast enhancement were visible (Table 4 and Fig. 1).  
 
Comparisons between postoperative and non-postoperative events in the GGN patient population 
Ischemic strokes (Table 5) 
43/70 (61%) occurred postoperatively and 27/70 (39%) without relation to surgery. Patient age was 
lower in the group of patients with postoperative events than in non-postoperative events (53 years 
vs. 61 years, p=0.098). Tumor entities were distributed without difference (p=0.582). The rate of 
severe disability did not differ between postoperative and non-postoperative brain infarctions (MRS 
> 3: 71 % vs. 59 %, p=0.401). Patients with postoperative brain infarctions showed a significantly 
lower rate of cerebrovascular risk factors (38 % with at least one risk factor) than patients with non-
postoperative events (73% with at least one risk factor, p=0.014). In 14 of 27 (52%) patients with 
non-postoperative ischemic strokes radiotherapy to the involved part of the brain was part of the 
treatment a median of 1.5 years before the event. In all these patients ischemic stroke pattern did not 
seem cardiogenic. 8/14 patients did not show any cardiovascular risk factors. In 1 of 14 patients an 
intracranial arterial stenosis was documented. 
 
Intracranial hemorrhages (Table 6) 
Of all ICH, 68% (83/123) occurred within 7 days after tumor resection, whereas 32% (40/123) 
occurred without close timely relation to surgery. Distribution of glioma type showed more grade III 
tumors (30% vs. 9%) in the non-postoperative ICH. Particularly, tumors with oligodendroglial and 
oligoastrocytic histology showed more often non-postoperative than postoperative bleeding (13% 
vs. 1%).  
Types of ICH differed significantly in their distribution between postoperative and non-
postoperative events (p=0.002). Intraparenchymal bleeding was recorded about equally often (71% 
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vs. 75%), whereas epidural hematoma occurred more often postoperatively (17% vs. 0%).  Subdural 
(20% vs. 11%) und subarachnoidal hematomas (5% vs. 0%) were more often recorded non-
postoperatively. Severe disability was registered more often in postoperative bleeding (MRS > 3: 
49% vs. 21%, p=0.008), but other confounding factors like a surgery-related neurological deficit 
cannot be excluded to contribute to this. 
Risk factors for ICH were documented in 35% of cases in postoperative ICH and in 32% of non-
postoperative ICH (p=0.779). 
 
Deep venous thromboembolism (Table 7) 
DVT occurred in 23/130 (18%) of the events within 7 days after tumor resection and in 50/130 
(38%) within 4 weeks after tumor surgery. 
In the group of non-postoperative DVT patients were of older median age (59 ys vs. 51 ys, 
p=0.018). Glioma types were distributed without difference in the two groups (p=0.623). Median 
steroid dose was not different between the two groups (median 1 mg vs. 2 mg, p=0.622). 
Non-postoperative DVT were diagnosed in 22/106 (22%) during running radio-(chemo-)therapy, 
15% during chemotherapy with temozolomide, 10% during therapy with nitrosourea, and 6% 
during therapy with BEV. The proportion of severe DVT with pulmonary embolism was lower in 
non-postoperative events (40% vs. 56%) without reaching statistical significance (p=0.133).   
 
Discussion 
The present non-interventional observation study provides relevant information on the frequency of 
the main vascular events in a carefully prospectively documented relevant cohort of patients with 
gliomas. As the participating centers included patients based on the availability of biomaterial from 
the surgery, this analysis provides a clear overview on the natural course of development of vascular 
complications in gliomas. Limitations of the present data are the only cursory monitorings that have 
been done on original chart data and that numbers in the GGN cohort not necessarily reflect the 
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global incidence of glioma subgroups, as the GGN has certain priority topics in low-grade and 
anaplastic gliomas. In our cohort the rate of GB/malignant glioma was lower than in the Central 
Brain Tumor Registry of the United States (CBTRUS; GGN: 46,3% vs. CBTRUS: 61,0%). The rate 
of grade III and II astrocytoma and oligodendroglioma was with 39.6% much higher in our cohort 
than in CBTRUS (23.7%). The rates of PA (GGN: 3.0%, CBTRUS 5.2%) and of others/unknown 
(GGN: 11.1%, CBTRUS 10.1%) were similar [1]. 
 
Ischemic strokes 
Data about the frequency of brain infarction in patients with glioma are rare. In a retrospective 
review of Kreisl et. al [13], in which glioma (60%) and other tumor types such as meningioma and 
CNS-Lymphoma were included minimum ischemic stroke rate was 1.3% in a population of 5,100 
patients. In our study, which is the first only focussing on gliomas, the rate of brain infarction is 
70/3889 patients (1.8%) and therefore in the same range. Here, there were no differences according 
to WHO grade.  
Most ischemic strokes (61%) occurred postoperatively and less often the common cerebrovascular 
risk factors could be detected than in non-postoperative strokes. This observation of a relevant 
incidence of postoperative ischemic lesions, often explaining an otherwise unexplainable worsening 
had been thoroughly followed with DWI studies in the past [29]. Outcome of postoperative versus 
non-surgery-related ischemias was not different. With anti-angiogenic BEV therapy more ischemic 
strokes were documented than without that therapy (6.1 versus 0.6%). This appears surprising, as 
this was not observed in other studies with glioma [7] (ischemic stroke rate: 1.9%, no control group) 
or in side effect monitoring in other extra-cranial tumor entities [18], [26]. On the other hand 
intracerebral diffusion-restricted sites in glioma are well appreciated to occur with BEV-therapy 
[19], [9]. The origin and nature of these diffusion-restricted areas are controversially discussed, 
therapy-associated hypoxic areas in proximity of the tumor [20] or cell dense tumor areas due to 
altered tumor growth [17] could be relevant causes. In our MRI analysis diffusion-restriction was 
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confined to lacunar areas in proximity of tumors, while contrast enhancement in the remaining 
tumor was decreasing. This allows for both or an overlap of both explanations.  
The high rate of BEV-induced diffusion-restricted sites in glioma patients points to a growth-related 
specific effect in this tumor entity. These diffusion-restrictions can be associated with neurologic 
deterioration and should not be seen as harmless side effects, although there might be a relevant 
number of non-reported asymptomatic cases. In the work of Rieger et al. [19] 13 (72%) of 18 
analysed patients showed diffusion-restricted sites. The diffusion-restricted areas may even predate 
contrast enhancing tumor progression, e.g. in more than 80% of cases reported by Gupta et al. [9], 
and thus might be nothing but another correlate of progressive disease.  
Eventually, a diffusion-restriction next to the tumor under therapy with BEV with neurological 
worsening may in most cases may be no „classic“ ischemic stroke due to thrombotic or embolic 
vessel occlusion but rather a local effect of therapy. It would not be justified to assume an elevated 
risk of macroangiopathic or embolic stroke under BEV-therapy. The exact risk for diffusion-
restriction with neurologic worsening should be determined in the context of the ongoing phase III 
trials (e.g. Avaglio, NCT00943826, [21]). 
 
Intracranial hemorrhage 
The frequency of non-postoperative ICH in glioma varies from 2-25% in the literature [10], [22], 
[27]. The postoperative risk for ICH is about 2-5% [6], [23]. 
In our study ICH was registered in 3.2% of all patients, two thirds of events occurred within 7 days 
after surgery. 
Overall, there was an increase of bleeding rate with WHO-grade of the glioma. It remains unclear 
from our data, if this is an effect of a higher number of resections in malignant gliomas. Among 
anaplastic tumors a relevant number of non-postoperative ICH occurred in tumors with 
oligondendroglial or oligoastrocytic differentiation. This might reflect the fact that in these tumors a 
tendency for spontaneous bleeding is known [14]. 
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Among non-postoperative ICH subdural hemorrhages were more frequent. The latter and the fact 
that many non-postoperative ICH start intratumorally without initial major neurologic deficit might 
explain the observed better outcome of spontaneous bleedings.  
Interestingly, only in about one third of cases in postoperative and non-postoperative ICH bleeding 
risk factors were reported. This supports the fact that the majority of non-postoperative hemorrhage 
indeed arise „spontaneously“ due to fragile tumor blood vessels. 
With BEV-therapy among 81 patients only one ICH (according to a rate of 1.2%) was observed, 
which gives a similar rate of non-postoperative hematoma as in patients that have never been 
treated with BEV (1.0%) and does not support an elevated risk of ICH during BEV therapy, with the 
limitation of the small number of patients observed in our study. 
Comparable results were observed by Friedman et al. (ICH-rate under BEV 2,4%, with irinotecan 
3.8%, no control group) [8]. In BEV-treated patients with primary extracranial tumors an ICH rate 
of 3.7% [12] and of 1-2% in patients with intracerebral metastases [2] was not significantly 
elevated. 
 
Deep venous thromboembolism 
Data about DVT show an extensively varying probability of 4-30% to develop DVT during course 
of glioma disease [15], [3], [5], [25], [24]. Generally, large studies with some thousand patients 
show smaller rates than small prospective studies with less than hundred patients. Our rate of 143 
events in 2855 patients (5%) is in the low range.  
A correlation between the rate of DVT and the WHO Grade of glioma has been observed before 
[15], [3]. This may not only reflect a higher degree of disability in patients, more intensive 
concomitant therapies or increasing steroid dose, but may be a specific prothrombotic, 
paraneoplastic effect of malignant gliomas [11]. 
A high rate of DVT has also been found in studies with BEV in malignant glioma (1.6%-12.5%, 
discussed in [4]). Larger comparing analyses with BEV-naive control groups only exist for other 
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tumor entities and showed a moderately increased relative risk for DVT of 1.33 [16]. Facing the per 
se very high DVT risk in malignant glioma compared to other tumor entities, our result of only a 
trend to a higher DVT rate under BEV indicates that the specificity of this risk for BEV treatments 
in glioblastoma may have been overestimated. Nonetheless, interpretation is weakened by the low 
number of BEV treated patients in our cohort.   
The comparison of postoperative and non-postoperative DVT did not show significant differences 
of outcome and other parameters. Patients with non-postoperative DVT were older, which might 
support the fact that age in itself is a risk factor for DVT [24]. 
 
Summary 
This study shows current rates and characteristics of vascular complications in patients with glioma.  
Compared to earlier studies relatively low rates of ICH and DVT were reported, which might be 
due to a high proportion of low-grade gliomas in our patient cohort. 
Under the therapy with BEV symptomatic, therapy associated intracerebral diffusion restrictions 
were seen in a relevant amount of cases.  
There was a trend for a higher DVT rate under therapy with BEV. No difference appeared in the 
frequency of ICH. These findings should with respect to our small event numbers in the BEV group 
be controlled in the ongoing phase III studies.   
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Table 1: Characteristics of GGN patient population and number of vascular events 
 
 GGN patients 
(N=3889) 
Glioma type 
- GB  
- AA/AOA/AOD  
- AII/ODII/OAII  
- PA  
- other/unknown 
 
1800 (46.3%) 
646   (16.6%) 
896   (23.0%) 
115   (3.0%) 
432   (11.1%) 
Ischemic strokes, N (%) 70   (1.8%) 
ICH, N (%) 123 (3.2%) 
DVTa,, N (%) 143 (5.0%) 
 
Abbreviations: (A)A: (anaplastic) astrocytoma; (A)OA: (anaplastic) oligoastrocytoma; (A)OD: 
(anaplastic) oligodendroglioma; DVT: deep venous thrombosis; ICB: intracranial bleeding; GB: 
glioblastoma; PA: pilocytic astrocytoma 
 
a of 2855 patients 
 
Table 2: Distribution of vascular events according to glioma type 
 
Event  Glioma type p-value 
 AII/OAII/ODII AA/AOA/AO GB  
Ischemic stroke, N (%) 13/896 (1.5%) 14/646 (2.2%) 40/1800 (2.2%) 0.383 
ICH, N (%) 13/896 (1.5%) 20/646 (3.1%) 88/1800 (4.9%) <0.001 
DVT, N (%) 13/653 (2.0%) 18/471 (3.8%) 98/1361 (7.2%) <0.001 
 
Abbreviations: (A)A: (anaplastic) astrocytoma; (A)OA: (anaplastic) oligoastrocytoma; (A)OD: 
(anaplastic) oligodendroglioma; DVT: deep venous thrombosis; ICB: intracranial bleeding; GB: 
glioblastoma  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: Number of non-postoperative vascular events and distribution of glioma type among 
patients with BEV treatment and patients never been treated with BEV 
 
 Non BEV-treated 
(N=3808) 
BEV-treated  
(N=81) 
p-value 
Ischemic strokes, N (%) 
 
22 (0.6%) 5 (6.1%) <0.001 
ICH, N (%)  39 (1.0%) 1 (1.2%) 0.571 
 
DVT, N (%) 100 (3.6%) a 6 (7.4%) 0.123 
 
Glioma type 
 
-  GB  
-  AA/AOA/AO  
-  AII/OAII/ODII  
-  PA  
-  Other/unkown 
 
 
1742 (45.7%) 
633  (16.6%) 
891 (23.4%) 
405 (10.6%) 
137 (3.6%) 
 
 
58 (71.6%) 
13 (16.0%) 
5 (6.2%) 
0 (0%) 
5 (6.2%) 
 
 
<0.001 
 
Abbreviations: (A)A: (anaplastic) astrocytoma; (A)OA: (anaplastic) oligoastrocytoma; (A)OD: 
(anaplastic) oligodendroglioma; BEV: bevacizumab; DVT: deep venous thrombosis; ICB: 
intracranial bleeding; GB: glioblastoma  
 
a of 2774 patients 
 
Table 4: Characteristics of BEV-associated ischemic strokes 
 
Nr Age 
[years]  
Localisation of 
diffusion-
restriction 
Next to 
contrast 
enhancing 
tumor 
Glioma type Risk factors MRS 
(after 
event) 
R to BEV 
at time of 
event  
1 67 Paraventricular 
white matter, basal 
ganglia 
Yes OAIII  None  5 PR 
2 63 Paraventricular 
white matter, basal 
ganglia 
Yes GB None  3 PR  
3 63a Paraventricular 
white matter  
MRI NA GB  None  6 PR 
4 59 Thalamus, mesial 
temporal lobe 
Yes GB  AH, Plaques 
ACI, 
infiltration 
of  MCA 
3 PR 
5 69 Thalamus MRI NA GB  ACC-Plaque 3 PR 
 
Abbreviations: ACC: Common cerebral artery, ACI: Internal carotid artery, AH: Arterial 
hypertension, CE: contrast enhancement, DR: diffusion-restriction, MCA: Median cerebral artery, 
MRI: magnetic resonance imaging, MRS: modified rankin score, NA: not available; Nr: number; 
PR: partial response, R: response, RT: radiotherapy 
 
a second event of patient with event Nr 2 
Table 5: Characteristics of patients with ischemic strokes 
 
 N=70  
 Postoperative (N=43)  Non-postoperative (N=27)  p-value 
Age [years], Median (Range) 53 (25-78) 61 (39-84) 0.098 
Glioma type 
 
GB  
AA/AOA/AO  
AII/OAII/ODII  
Other 
 
 
26/43 (61%) 
8/43 (19%) 
7/43 (16%) 
2/43 (5%) 
 
 
14/27 (52%) 
6/27 (22%) 
7/27 (26%) 
0/27 (0%) 
 
 
0.582 
 
Outcome 
  
MRS ≤ 3 
MRS > 3 
of which 
MRS = 6  
 
 
10/34 (29%) 
24/3 (71%) 
 
5/34  (15%) 
 
 
9/22 (41%) 
3/22 (59%) 
 
1/22  (5%) 
 
 
0.401 
 
Risk factor  
 
None 
 
Arterial hypertension 
Diabetes mellitus 
Persisting foramen ovale 
Other (incl. AF) 
 
 
18/29 (62%) 
 
8/29 (28%) 
0/29 (0%) 
0/29 (0%) 
3/29 (10%) 
 
 
6/22 (27%) 
 
5/22 (23%) 
3/22 (14%) 
3/22 (14%) 
5/22 (23%) 
 
 
0.014 
 
Abbreviations: : (A)A: (anaplastic) astrocytoma; (A)OA: (anaplastic) oligoastrocytoma; (A)OD: 
(anaplastic) oligodendroglioma; AF: atrial fibrillation; GB: glioblastoma; MRS modified Rankin 
score 
Table 6: Characteristics of patients with intracranial bleeding 
 
 N=123  
 Postoperative (N=83)  Non-postoperative (N=40) p-value 
Age [years], Median (Range) 59  (18-85) 54  (27-85) 0.867 
Glioma type 
 
GB  
 
AA 
AOA/AO 
 
AII 
OAII/ODII  
 
PA 
Ependymoma 
 
 
64/83 (77%) 
 
7/83 (8%) 
1/83 (1%) 
 
9/83 (11%) 
0/83 (0%) 
 
1/83 (1%) 
1/83 (1%) 
 
 
24/40 (60%) 
 
7/40 (17%) 
5/40 (13%) 
 
2/40 (5%) 
2/40 (5%) 
 
0/82 (0%) 
0/82 (0%) 
 
 
0.038a 
 
Bleeding type 
 
Intracerebral 
Epidural 
Subdural 
Subarachnoidal  
 
 
59/83 (71%) 
14/83 (17%) 
9/83 (11%) 
0/83 (0%) 
 
 
30/40 (75%) 
0/40 (0%) 
8/40 (20%) 
2/40 (5%) 
 
 
0.002 
 
Outcome 
  
MRS ≤ 3 
MRS > 3 
of which 
MRS=6 
 
 
38/75 (51%) 
37/75 (49%) 
 
12/75 (16%) 
 
 
23/29 (79%) 
6/29 (21%) 
 
4/29 (14%) 
 
 
0.008 
 
Risk factors  
 
None 
   
Arterial hypertension  
Thrombocytopenia 
Heparinisation 
Aspirine use 
 
 
35/54 (65%) 
 
14/54 (26%) 
3/54 (6%) 
2/54 (4%) 
1/54 (2%) 
 
 
15/22 (68%) 
 
6/22 (27%) 
1/22 (5%) 
1/22 (5%)  
0/22 (0%) 
 
 
0.779 
 
 
Abbreviations: : (A)A: (anaplastic) astrocytoma; (A)OA: (anaplastic) oligoastrocytoma; (A)OD: 
(anaplastic) oligodendroglioma; AF: atrial fibrillation; GB: glioblastoma; MRS modified rankin 
score; PA: pilocytic astrocytoma 
aGlioma were grouped according to WHO grade. 
 
Table 7: Characteristics of patients with deep venous thromboembolism 
 
 N= 143; relation to therapy known in 130 cases 
 Postoperative  
(N=23/130 in 7 days) 
Non-postoperative 
(N=106/130) 
p-value 
Age [years], Median (Range) 51 (26-78) 59 (24-81) 0.018 
Glioma type 
 
GB 
AA/AOA/AO 
AII/OAII/ODII 
Other/unknown 
 
 
 
16/23 (70%) 
4/23 (17%) 
3/23 (13%) 
0/23 (0%) 
 
 
82/106 (77%) 
14/106 (13%) 
10/106 (10%) 
0/106 (0%) 
 
 
0.623 
 
Parallel therapy 
 
None 
   
Radio(-chemo)therapy 
   
Temozolomide 
Nitrosourea 
Bevacizumab 
Other 
   
 
 
22/22 (100%) 
 
0/22 (0%) 
 
0/22 (0%) 
0/22 (0%) 
0/22 (0%) 
0/22 (0%) 
 
 
 
31/89 (35%) 
 
22/89 (25%) 
 
16/89 (18%) 
11/89 (12%) 
6/89 (7%) 
3/89 (3%) 
 
 
 
ND 
Steroid use 
 
None 
 
Steroid dose at patients 
discharge, median (range) 
 
 
3/8 (38%) 
 
 
1 mg/d (0-16 mg) 
 
 
19/42 (45%) 
 
 
2 mg/d  (0-24 mg) 
 
 
1.000 
 
 
0.622 
Outcome 
 
No pulmonary embolism 
Pulmonary embolism 
 
Pulmonary embolism + death 
 
 
10/23 (43%) 
13/23 (57%) 
 
1/23 (4%) 
 
 
63/104 (61%) 
41/104 (49%) 
 
4/104 (4%) 
 
0.133  
 
 
 
 
Abbreviations: : (A)A: (anaplastic) astrocytoma; (A)OA: (anaplastic) oligoastrocytoma; (A)OD: 
(anaplastic) oligodendroglioma; GB: glioblastoma; pilocytic astrocytoma: PA;  ND Not done 
 
 
 
 
 
 
 
 
 
 
Fig MRI of ischemic strokes occurring under BEV                      
Diffusion-
Weighted
MRI 
Contrast 
enhanced 
T1 MRI
Abbreviations: BVC: bevacizumab, MRI: magnetic resonance imaging, T1: T1 relaxation time 
a patient 1                         b  patient 2                         c  patient 4
